Male BRCA2 mutation carriers are recommended to undergo prostate cancer surveillance through measuring PSA, digital rectal exams, and prostate USG over 40 years of age, and this could also be considered for BRCA1 mutation carriers. Here, KLK3 is linked to prostate carcinoma.